EUROCOVER-CLL: Reimbursement and accessibility of new treatments in relapsed/refractory chronic lymphocytic leukemia.

Front Pharmacol · 2025 · PMC12436112 · PMID 40963690

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

of borderline significancep = 0.050actually significant

Additionally, positive correlations were observed with CLL incidence and CLL-related deaths, although they were of borderline significance (both at p = 0.050).

also in 2,624 other papers

borderline significantp = 0.050actually significant

Borderline significant associations were noted for CLL incidence and mortality (p = 0.050).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.